Robert L. Diaz

Abstract 1605: Personalization of cancer treatments with a CLIA-certified high-complexity and high-throughput drug sensitivity test

Eduardo Mendez, Brady Bernard, Michael Churchill, 2018 .

Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer

Adam A. Margolin, Hallie A. Swan, Robert L. Diaz, 2018, Clinical Cancer Research.

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer

Hallie A. Swan, Robert L. Diaz, E. Swisher, 2020, EBioMedicine.

Predictive value of a CLIA-approved organoid based drug sensitivity test.

Robert L. Diaz, Shalini C. Pereira, C. Grandori, 2020 .

CHOLANGIOCARCINOMA FOUNDATION ANNUAL MEETING 2020: ABSTRACT https://cholangiocarcinoma.org/2020-annual-conference Title: ORGANOID BASED FUNCTIONAL TEST TO PREDICT PERSONALIZED TREATMENT IN CHOLANGIOCARCINOMA

Hallie A. Swan, Robert L. Diaz, Shalini C. Pereira, 2020 .

Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

Robert L. Diaz, E. Swisher, C. Grandori, 2021, Molecular Cancer Therapeutics.

Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing

Hallie A. Swan, Robert L. Diaz, Shalini C. Pereira, 2023, NPJ precision oncology.

Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma

Robert L. Diaz, Shalini C. Pereira, C. Grandori, 2024, Frontiers in oncology.